Giulia Rotta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giulia Rotta has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Elsayed
Philochem AG, Otelfingen, Switzerland
35 shared publications - Dario Neri
Philochem AG, Otelfingen, Switzerland
35 shared publications - Christian Pellegrino
University and University Hospital of Zürich 1 Department of Medical Oncology and Hematology Zürich, Switzerland
34 shared publications - Emanuele Puca
Philochem AG, Otelfingen, Switzerland
34 shared publications - Markus Gabriel Manz
Department of Medical Oncology and Hematology University Hospital Zurich and University of Zurich Zürich Switzerland
34 shared publications - Sheila Dakhel Plaza
Philochem AG, CH-8112 Otelfingen, Switzerland
34 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Movie S1 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
Movie S1 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessMovie S1 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
Movie S1 from Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer
- 13 February 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (3) , 1996-2005
Combination with Immunocytokines Enhances the Anticancer Activity of Small Molecule Drug Conjugates and Radioligand Therapeutics Targeting Fibroblast Activation Protein
The targeted delivery of radionuclides and cytotoxic drugs represents a viable alternative to conventional chemotherapy, aiming to improve therapeutic efficacy and reduce systemic toxicity by selective accumulation of the active payload at the tumor site. Our group has developed radioligand therapeutics (RLTs) and small molecule-drug conjugates (SMDCs) targeting fibroblast activation protein (FAP), a tumor-associated antigen abundantly and selectively expressed in the majority of solid human malignancies. Among these, 177Lu-OncoFAP-23 and OncoFAP-GlyPro-MMAE showed selective accumulation in FAP-positive tumors in murine models and demonstrated potent anticancer activity. To further enhance the therapeutic efficacy, combining targeted drugs with immunotherapy may provide synergistic benefits by engaging both direct tumor cell killing and immune system activation. In this work, we explored the combination of FAP-targeting cytotoxic and radioactive therapeutics with three different immunocytokines targeting the Extra Domain B (EDB) of fibronectin: L19-hIL2, L19-mIL12, and L19-mTNF. A therapy experiment in immunocompetent mice bearing low FAP-expressing tumors showed that the combination with L19-hIL2 potentiated the antitumoral activity of 177Lu-OncoFAP-23 and OncoFAP-GlyPro-MMAE. These results provided the motivation for the clinical development of these combinations for treating FAP-positive solid tumors.
- 13 February 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (3) , 1996-2005
Combination with Immunocytokines Enhances the Anticancer Activity of Small Molecule Drug Conjugates and Radioligand Therapeutics Targeting Fibroblast Activation Protein
The targeted delivery of radionuclides and cytotoxic drugs represents a viable alternative to conventional chemotherapy, aiming to improve therapeutic efficacy and reduce systemic toxicity by selective accumulation of the active payload at the tumor site. Our group has developed radioligand therapeutics (RLTs) and small molecule-drug conjugates (SMDCs) targeting fibroblast activation protein (FAP), a tumor-associated antigen abundantly and selectively expressed in the majority of solid human malignancies. Among these, 177Lu-OncoFAP-23 and OncoFAP-GlyPro-MMAE showed selective accumulation in FAP-positive tumors in murine models and demonstrated potent anticancer activity. To further enhance the therapeutic efficacy, combining targeted drugs with immunotherapy may provide synergistic benefits by engaging both direct tumor cell killing and immune system activation. In this work, we explored the combination of FAP-targeting cytotoxic and radioactive therapeutics with three different immunocytokines targeting the Extra Domain B (EDB) of fibronectin: L19-hIL2, L19-mIL12, and L19-mTNF. A therapy experiment in immunocompetent mice bearing low FAP-expressing tumors showed that the combination with L19-hIL2 potentiated the antitumoral activity of 177Lu-OncoFAP-23 and OncoFAP-GlyPro-MMAE. These results provided the motivation for the clinical development of these combinations for treating FAP-positive solid tumors.